Prox1-CreERT2 Mouse

Random Transgenic

Prox1-CreERT2 Random Transgenic Mouse Model
This line is cryopreserved and requires cryorecovery.

C57BL6 Background

  • Model #
  • Genotype
  • Nomenclature
  • 14092-F
  • 14092-M
  • An inducible cre deleter under the control of the prospero homeobox 1 (Prox1) promoter.
  • Cre recombination is inducible via administration of tamoxifen.
  • Allows specific and temporally controlled cre-loxP recombination (gene inactivation/activation) in Prox1-expressing tissues, including lymphatic endothelia.
  • Efficient recombination is observed during all developmental stages (embryonic, postnatal) and in adults.

    Genetic Background:



    The Prxo1-creERT2 mouse was developed in the laboratory of Taija Makinen at the London Research Institute. A cDNA encoding tamoxifen inducible Cre recombinase (CreERT2) followed by SV40 polyadenylation signal was introduced into the start codon of Prox1 in BAC clone RP23-190F21 using homologous recombination in bacteria. Founder lines were backcrossed to C57BL/6. Taconic received embryos from CRT in 2015.



    Initial Publication:

    Bazigou et al. 2011. Genes regulating lymphangiogenesis control venous valve formation and maintenance in mice. J Clin Invest. Aug 1; 121(8): 2984–2992.

  • Access to this model requires execution of a Limited Breeding Agreement and cryorecovery services to recover the line. Current Limited Breeding Agreement fees for this model are $3,000/€2550 per year for non-profit users and $10,000/€8500 per year for for-profit users. Cryorecovery fees are additional.

    Welcome! Tell us a little about yourself